DDInter1863 DDInter1658
Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola gigantica_, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452]
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Triclabendazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Triclabendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostemsavir
Triclabendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Triclabendazole {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Triclabendazole {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Triclabendazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Triclabendazole may lead to a major life threatening interaction when taken with Vemurafenib
Triclabendazole may lead to a major life threatening interaction when taken with Ivosidenib